FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Laurus Labs IPO is a book built issue of Rs 1,331.80 crores. The issue is a combination of fresh issue of 0.7 crore shares aggregating to Rs 300.00 crores and offer for sale of 2.41 crore shares aggregating to Rs 1,031.80 crores.
Laurus Labs IPO bidding started from December 6, 2016 and ended on December 8, 2016. The allotment for Laurus Labs IPO was finalized on Wednesday, December 14, 2016. The shares got listed on BSE, NSE on December 19, 2016.
Laurus Labs IPO price band is set at ₹426 to ₹428 per share. The minimum lot size for an application is 35 Shares. The minimum amount of investment required by retail investors is ₹14,980.
Citigroup Global Markets India Private Limited, Jefferies India Private Limited, Kotak Mahindra Capital Company Limited and SBI Capital Markets Limited are the book running lead managers of the Laurus Labs IPO, while Kfin Technologies Limited is the registrar for the issue.
Refer to Laurus Labs IPO RHP for detailed information.
IPO Date | December 6, 2016 to December 8, 2016 |
Listing Date | December 19, 2016 |
Face Value | ₹10 per share |
Price Band | ₹426 to ₹428 per share |
Lot Size | 35 Shares |
Total Issue Size | 31,116,785 shares (aggregating up to ₹1,331.80 Cr) |
Fresh Issue | 7,009,345 shares (aggregating up to ₹300.00 Cr) |
Offer for Sale | 24,107,440 shares of ₹10 (aggregating up to ₹1,031.80 Cr) |
Issue Type | Book Built Issue IPO |
Listing At | BSE, NSE |
Share holding pre issue | 98,746,904 |
Share holding post issue | 105,756,249 |
Laurus Labs IPO offers 21,911,308 shares. 6,174,544 (28.18%) to QIB, 4,623,879 (21.10%) to NII, 10,789,051 (49.24%) to RII, 323,834 (1.48%) to employees. 308,258 RIIs will receive minimum 35 shares and (sNII) and (bNII) will receive minimum 490 shares. (in case of oversubscription)
Investor Category | Shares Offered | Maximum Allottees |
---|---|---|
Anchor Investor Shares Offered | - | NA |
QIB Shares Offered | 6,174,544 (28.18%) | NA |
NII (HNI) Shares Offered | 4,623,879 (21.10%) | |
Retail Shares Offered | 10,789,051 (49.24%) | 308,258 |
Employee Shares Offered | 323,834 (1.48%) | NA |
Total Shares Offered | 21,911,308 (100%) |
Laurus Labs IPO opens on December 6, 2016, and closes on December 8, 2016.
IPO Open Date | Tuesday, December 6, 2016 |
IPO Close Date | Thursday, December 8, 2016 |
Basis of Allotment | Wednesday, December 14, 2016 |
Initiation of Refunds | Thursday, December 15, 2016 |
Credit of Shares to Demat | Friday, December 16, 2016 |
Listing Date | Monday, December 19, 2016 |
Cut-off time for UPI mandate confirmation | 5 PM on December 8, 2016 |
Investors can bid for a minimum of 35 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.
Application | Lots | Shares | Amount |
---|---|---|---|
Retail (Min) | 1 | 35 | ₹14,980 |
Retail (Max) | 13 | 455 | ₹194,740 |
Lot Size Calculator |
Incorporated in 2005, Laurus Labs Ltd is Hyderabad based pharmaceutical company. Laurus Labs is in the business of manufacturing generic active pharmaceutical ingredients (APIs) for therapeutic areas of antiretrovirals (ARVs) and Hepatitis C. Company also manufacture APIs in oncology and other therapeutic areas.
Laurus Labs operates in four business lines:
1. Generics active pharmaceutical ingredients (APIs) - The development, manufacture and sale of APIs and advanced intermediates.
2. Generics finished dosage forms (FDFs) - The development and manufacture of oral solid formulations.
3. Synthesis - Contract development and manufacturing services for global pharmaceutical companies.
4. Ingredients - The manufacture and sale of specialty ingredients for use in the nutraceutical and cosmeceutical sectors.
Key Highlights:
1. Laurus Labs launched 59 products since our inception in 2005.
2. Nine out of the 10 largest generic pharmaceutical companies in the world are its customers.
3. Laurus Labs employed 587 scientists at our R&D center in Hyderabad and 12 scientists at R&D centre in Greater Boston USA.
4. The Company owned 32 patents and had 150 pending patent applications, in several countries.
5. Company has three manufacturing facilities in Visakhapatnam, Andhra Pradesh.
6. Company sells its products in 32 countries in Sub-Saharan Africa, South-East Asia and Latin America.
Key Strengths:
1. Leadership in APIs in Select, High Growth Therapeutic Areas
2. Strong R&D Capabilities and Process Chemistry Skills
3. Industry Leading, Modern and Regulatory Compliant Manufacturing Capacities
4. Long-standing Relationships with Multi-National Pharmaceutical Companies
5. Experienced Promoters and Qualified Operational Personnel
6. Established Track Record of Delivering Growth
Particulars | For the year/period ended (in Rs. Million) | ||||
---|---|---|---|---|---|
31-Mar-16 | 31-Mar-15 | 31-Mar-14 | 31-Mar-13 | 31-Mar-12 | |
Total Assets | 23,083.48 | 18,925.49 | 12,730.58 | 7,009.89 | 5,128.78 |
Total Revenue | 17,884.15 | 13,603.80 | 11,685.34 | 7,235.67 | 4,523.07 |
Profit After Tax (PAT) | 1,435.68 | 735.17 | 972.17 | 882.19 | 215.77 |
The object of the issue are to:
1. Pre-payment of term loans; and
2. General corporate purposes.
[Dilip Davda] Company is having good contracts from world leaders and enjoys leadership position in APIs and generics. Investments made by the company will start adding to revenues and profits from FY 18 onwards and thus poised for bright prospects. Although issue appears to have been priced in line with peer’s trending, it may be considered for medium to long term investment. Read detail review...
The Laurus Labs IPO is subscribed 4.53 times on December 8, 2016 6:18:00 PM. The public issue subscribed 1.58 times in the retail category, 10.54 times in the QIB category, and 3.57 times in the NII category. Check Day by Day Subscription Details (Live Status)
Category | Subscription (times) |
---|---|
QIB | 10.54 |
NII | 3.57 |
Retail | 1.58 |
Employee | 1.71 |
Total | 4.53 |
Listing Date | December 19, 2016 |
BSE Script Code | 540222 |
NSE Symbol | LAURUSLABS |
ISIN | INE947Q01010 |
Final Issue Price | ₹428 per share |
Price Details |
---|
Final Issue Price |
Open |
Low |
High |
Last Trade |
BSE |
---|
₹428.00 |
₹490.00 |
₹475.00 |
₹498.00 |
₹480.50 |
NSE |
---|
₹428.00 |
₹489.90 |
₹475.00 |
₹498.00 |
₹480.40 |
Laurus Labs Ltd
Plot No.21,
Jawaharlal Nehru Pharma City,
Parawada, Visakhapatnam 531 021
Phone: + 91 40 3980 4333
Email: secretarial@lauruslabs.com
Website: http://www.lauruslabs.com
Kfin Technologies Limited
Phone: 04067162222, 04079611000
Email: einward.ris@karvy.com
Website: https://kosmic.kfintech.com/ipostatus/
Laurus Labs IPO is a main-board IPO of 31,116,785 equity shares of the face value of ₹10 aggregating up to ₹1,331.80 Crores. The issue is priced at ₹426 to ₹428 per share. The minimum order quantity is 35 Shares.
The IPO opens on December 6, 2016, and closes on December 8, 2016.
Kfin Technologies Limited is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
The Laurus Labs IPO opens on December 6, 2016 and closes on December 8, 2016.
Laurus Labs IPO lot size is 35 Shares, and the minimum amount required is ₹14,980.
You can apply in Laurus Labs IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Nuvama, ICICI Bank, HDFC Bank and SBI Bank.
The finalization of Basis of Allotment for Laurus Labs IPO will be done on Wednesday, December 14, 2016, and the allotted shares will be credited to your demat account by Friday, December 16, 2016. Check the Laurus Labs IPO allotment status.
Useful Articles
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|